Revvity, Inc. shared its third-quarter results and plans to possibly sell its Immunodiagnostics business in China for up to $200 million.

Nov 3, 2026, 10:15 AM ETResultsRead the original at SEC EDGAR

Neutral

The filing announces third-quarter results but gives no figures. The China IDX sale could bring up to $200 million, but it is conditional and the filing does not explain what giving up those assets means for Revvity, so its outlook is unchanged.

RVTY · Revvity, Inc.

AI read · Neutral

The AI's read

The filing gives no sales or profit figures, so this text does not show how the quarter went. The possible sale has a stated price limit, but Revvity would also transfer substantially all assets tied to that business, and closing remains subject to conditions. The filing does not explain the business's importance to Revvity, so the news does not point clearly in either direction.

Get alerts for RVTY

Follow Revvity, Inc. (RVTY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RVTY

Free on the App Store and Google Play, or on the web.